Scarica l'app Stockscreener
21.70
23.00%
-6.48
Dopo l'orario di chiusura:
22.50
0.80
+3.69%
Precedente Chiudi:
$28.18
Aprire:
$27.62
Volume 24 ore:
4.28M
Relative Volume:
3.97
Capitalizzazione di mercato:
$2.05B
Reddito:
-
Utile/perdita netta:
$-64.16M
Rapporto P/E:
-17.08
EPS:
-1.2702
Flusso di cassa netto:
$-69.06M
1 W Prestazione:
-19.45%
1M Prestazione:
+26.16%
6M Prestazione:
-43.91%
1 anno Prestazione:
-38.18%
Intervallo 1D:
$21.43
$28.56
Intervallo di 1 settimana:
$21.43
$30.23
Portata 52W:
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
Nome
Cg Oncology Inc
Settore
Industria
Telefono
(949) 419-6203
Indirizzo
400 SPECTRUM CENTER DRIVE, IRVINE
Confronta CGON con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
21.70 | 2.05B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-02 | Iniziato | JP Morgan | Overweight |
| 2025-04-16 | Iniziato | Scotiabank | Sector Perform |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2024-06-28 | Iniziato | BofA Securities | Buy |
| 2024-02-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Iniziato | Goldman | Neutral |
| 2024-02-20 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-14 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cg Oncology Inc Borsa (CGON) Ultime notizie
Here Are Reasons Why Cg Oncology Inc (NASDAQ: CGON) Is A Great Choice Now - Stocksregister
CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal
CG Oncology (NASDAQ:CGON) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of “Buy” by Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Invesco Ltd. - Defense World
CG Oncology initiated with an Overweight at JPMorgan - TipRanks
CGON Stock: JP Morgan Initiates Coverage with Overweight Rating - GuruFocus
JPMorgan Initiates Coverage on CG Oncology With Overweight Rating, $41 Price Target - marketscreener.com
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Ta - GuruFocus
CG Oncology (NASDAQ:CGON) Reaches New 1-Year Low After Insider Selling - Defense World
Why CG Oncology, Inc. (CGON) Surged on Monday - MSN
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Cg Oncology Inc’s (CGON) Stock Is Harder To Predict Than You Think - Stocksregister
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Wells Fargo & Company MN - Defense World
A look into Cg Oncology Inc (CGON)’s deeper side - Sete News
Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX
Could Cg Oncology Inc (NASDAQ: CGON) Be The Biggest Winner? - Marketing Sentinel
Barclays PLC Acquires 10,737 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology's Bladder Cancer Drug Impresses InvestorsHere's Why - AOL.com
Cg Oncology Inc [CGON] Stock sold by Insider POST LEONARD E for $28000.0 - knoxdaily.com
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? - MSN
TD Cowen Sticks to Its Buy Rating for CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Given Overweight Rating at Cantor Fitzgerald - Defense World
CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright - Defense World
CG Oncology shares jump on positive clinical trial data for cancer drug - Mugglehead Magazine
CG Oncology Stock (CGON) Surges 25% As Cancer Drug Shows Remarkable Results - TipRanks
J&J Looks To Overcome Drug-Delivery Limitations In Bladder Cancer With TAR-200 - insights.citeline.com
CG Oncology (CGON) Surges 25%: What Drove the Dramatic Stock Move? - Wealth Daily
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga
CG Oncology’s Blistering Rally: What You Need to Know - RagingBull
Cantor Fitzgerald maintains CG Oncology stock with $75 target - Investing.com Australia
CG Oncology Reports Durable Responses for Cretostimogene in Bladder Cancer Treatment; Shares Rise - marketscreener.com
Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe - Endpoints News
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug - inkl
This Small Biotech Rival To J&J Just Rocketed 44% - Investor's Business Daily
Cantor Fitzgerald maintains CG Oncology stock with $75 target By Investing.com - Investing.com India
Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings - Benzinga
Cg Oncology Inc (CGON) did well last session? - uspostnews.com
CG Oncology (CGON) Announces Phase 3 Trial Results Discussion - GuruFocus
Contrasting CG Oncology (CGON) & Its Rivals - Defense World
CGON Shows Promising Results in Bladder Cancer Study | CGON Stoc - GuruFocus
CGON: Insights on Phase 3 BOND-003 Trial Results for Bladder Can - GuruFocus
CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting - TipRanks
CG Oncology Reports Promising 24-Month Efficacy and Safety Data for Cretostimogene Monotherapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq
CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene Grenadenorepvec - TradingView
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting - The Globe and Mail
CG Oncology Bladder Cancer Drug Shows 42% Complete Response at 24 Months | CGON Stock News - Stock Titan
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025 - The Manila Times
CG Oncology's Breakthrough Phase 3 Bladder Cancer Treatment Data: What The AUA Plenary Will Reveal - Stock Titan
Daily Market Movement: Cg Oncology Inc (CGON) Sees a 0.34 Increase, Closing at 20.48 - DWinneX
Cg Oncology Inc Azioni (CGON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):